Antigenemia immunoassay for point of care dianostic melioidosis

抗原免疫分析用于诊断类鼻疽病的护理点

基本信息

  • 批准号:
    8260262
  • 负责人:
  • 金额:
    $ 28.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-05-01 至 2014-04-30
  • 项目状态:
    已结题

项目摘要

Status of laboratory diagnosis of melioidosis Currently, culture from multiple body sites is the gold standard for laboratory diagnosis. Culture requires experienced personnel and takes 3-4 days. Levels of bacteremia are very low (~ i CFU/ml). A point-of-care immunoassay for diagnosis of melioidosis could greatly impact patient outcome because a high percentage of patients with acute septicemia die within 24-48 h of admission, and the antibiotics used for empiric treatment of septicemia are not effective for B. pseudomallei. Assays for antibody have limited value due to an absence of antibody in the early stages of acute sepsis and a high level of background antibodies in endemic regions (6). Several studies reported PCR for detection of B. pseudomallei, but the reported lower limit of detection tends to fall above the range for the viable bacteria count in blood during human disease (118). Potential antigen targets for immunodiagnosis of melioidosis Detection of extracellular polysaccharides has been successful for a variety of bacterial infections. There are three candidate antigens for B. pseudomallei: the exopolysaccharide (EPS), the capsular polysaccharide (CPS), and the lipopolysaccharide (LPS). EPS is an unbranched polymer of a repeating tetrasaccharide: [-3)-p-D-Galp2Ac-(i-4)-a-D-Galp-(i-3)-p-D-Galp-(i-5)-|3-Kdo-(2-] (115). CPS is an unbranched homopolymer of [-3)-2-O-acetyl-6-deoxy-p-D-mannoheptopyranose-( i-] (120). LPS is an unbranched polymer of disaccharide repeating units having the basic structure: [-3-)-|3-D-glucopyranose-(i-3)-6-deoxy-a-L-talopyranose-(i-] (120). Melioidosis patients make antibodies to EPS, CPS and LPS, indicating that these antigens are produced in vivo. To date, no B. pseudomallei proteins have been identified as candidates for antigen-targeted diagnosis of melioidosis. The proposed InMAD process has the potential to identify B. pseudomallei antigens shed in vivo and may serve as a rapid broad discovery platform for many microbial threats.
类鼻疽实验室诊断现状目前,多部位培养是金 实验室诊断标准。文化需要有经验的人员,需要3-4天。级别 菌血症很低(~I cfu/ml)。一种诊断类鼻疽病的临床点免疫分析方法可以大大 影响患者预后,因为高比例的急性败血症患者在24-48小时内死亡 入院时,用于经验治疗败血症的抗生素对假鼻疽杆菌无效。 由于急性脓毒症的早期阶段没有抗体,抗体检测的价值有限 流行地区背景抗体水平较高(6)。已有多项研究报道了用聚合酶链式反应检测B。 但已报道的检测下限往往高于活细菌的范围 人类疾病期间的血液计数(118)。 类鼻疽免疫诊断的潜在抗原靶点胞外检测 多糖已经成功地治疗了多种细菌感染。假鼻疽杆菌有三种候选抗原:胞外多糖(EPS)、壳多糖(CPS)和脂多糖(LPS)。EPS是一种重复的四糖的未支化聚合物:[-3)-p-D-Galp2Ac-(i-4)-a-D-Galp-(i-3)-p-D-Galp-(i-5)-|3-Kdo-(2-](115)。CP是一种未支化的[-3)-2-O-acetyl-6-deoxy-p-D-mannoheptopyranose-(均聚物 I-](120)。脂多糖是一种无支化的双糖重复单元的聚合物,具有基本的 结构:[-3-)-|3-D-glucopyranose-(i-3)-6-deoxy-a-L-talopyranose-(i-](120)。类鼻疽患者会产生针对EPS、CPS和内毒素的抗体,这表明这些抗原是在体内产生的。到目前为止,还没有假鼻疽蛋白被确定为抗原靶向诊断类鼻疽病的候选蛋白。建议的InMAD过程有可能识别在体内脱落的假鼻疽抗原,并可能作为一个快速广泛的发现平台,以应对许多微生物威胁。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David P AuCoin其他文献

David P AuCoin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David P AuCoin', 18)}}的其他基金

Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples
急性莱姆病患者样本中尿液和血清特异性抗原的富集和验证
  • 批准号:
    10539304
  • 财政年份:
    2021
  • 资助金额:
    $ 28.71万
  • 项目类别:
Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples
急性莱姆病患者样本中尿液和血清特异性抗原的富集和验证
  • 批准号:
    10373787
  • 财政年份:
    2021
  • 资助金额:
    $ 28.71万
  • 项目类别:
Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)
用于早期诊断埃博拉病毒病 (EVD) 的即时抗原检测分析
  • 批准号:
    9910131
  • 财政年份:
    2020
  • 资助金额:
    $ 28.71万
  • 项目类别:
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
人类和非人类伯氏疏螺旋体诊断生物标志物的鉴定
  • 批准号:
    8783365
  • 财政年份:
    2014
  • 资助金额:
    $ 28.71万
  • 项目类别:
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
人类和非人类伯氏疏螺旋体诊断生物标志物的鉴定
  • 批准号:
    8892078
  • 财政年份:
    2014
  • 资助金额:
    $ 28.71万
  • 项目类别:
Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    9084470
  • 财政年份:
    2012
  • 资助金额:
    $ 28.71万
  • 项目类别:
Antigen Detection Assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8490302
  • 财政年份:
    2012
  • 资助金额:
    $ 28.71万
  • 项目类别:
Antigen Detection Assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8394825
  • 财政年份:
    2012
  • 资助金额:
    $ 28.71万
  • 项目类别:
Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8883363
  • 财政年份:
    2012
  • 资助金额:
    $ 28.71万
  • 项目类别:
Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8780682
  • 财政年份:
    2012
  • 资助金额:
    $ 28.71万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 28.71万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了